The multiple faces of NANOG in cancer: a therapeutic target to chemosensitize therapy-resistant cancers
- PMID: 34693722
- DOI: 10.2217/epi-2021-0228
The multiple faces of NANOG in cancer: a therapeutic target to chemosensitize therapy-resistant cancers
Abstract
The transcription factor NANOG regulates self-renewal and pluripotency in embryonic cells, and its downregulation leads to cell differentiation. Recent studies have linked upregulation of NANOG in various cancers and the regulation of expression of different molecules, and vice versa, to induce proliferation, metastasis, invasion and chemoresistance. Thus NANOG is an oncogene that functions by inducing stem cells' circuitries and heterogeneity in cancers. Understanding NANOG's role in various cancers may lead to it becoming a therapeutic target to halt cancer progression. The NANOG network can also be targeted to resensitize resistant cancer cells to conventional therapies. The current review focuses on NANOG regulation in the various signaling networks leading to cancer progression and chemoresistance, and highlights the therapeutic aspect of targeting NANOG in various cancers.
Keywords: NANOG; cancer; cancer stem cells; epigenetic modification; mutations; reprogramming.
Plain language summary
Lay abstract NANOG is a gene that is mainly expressed during development of the embryo. In adult tissues, NANOG is hardly expressed. In embryonal cells, NANOG is responsible for generating stem cells. Once the cells are differentiated into their specific function, they no longer need this renewing property. So expression of NANOG in differentiated ‘adult’ cells is harmful as it helps tumor cells to grow. NANOG expression also enables the tumor cells to keep on evolving their microenvironment, thus making it difficult for conventional therapy to destroy them. This review highlights the factors that influence NANOG’s expression in cancer progression and chemoresistance and how it can be targeted for therapy.
Similar articles
-
Nanog, as a key cancer stem cell marker in tumor progression.Gene. 2022 Jun 15;827:146448. doi: 10.1016/j.gene.2022.146448. Epub 2022 Mar 22. Gene. 2022. PMID: 35337852 Review.
-
Signaling pathways and microRNAs, the orchestrators of NANOG activity during cancer induction.Life Sci. 2020 Nov 1;260:118337. doi: 10.1016/j.lfs.2020.118337. Epub 2020 Aug 22. Life Sci. 2020. PMID: 32841661 Review.
-
New insight into NANOG: A novel therapeutic target for ovarian cancer (OC).Eur J Pharmacol. 2019 Jun 5;852:51-57. doi: 10.1016/j.ejphar.2019.03.003. Epub 2019 Mar 2. Eur J Pharmacol. 2019. PMID: 30831081 Review.
-
MAD2L1-mediated NANOG nuclear translocation: A critical factor in lung cancer chemoresistance.Cell Signal. 2025 Aug;132:111811. doi: 10.1016/j.cellsig.2025.111811. Epub 2025 Apr 14. Cell Signal. 2025. PMID: 40233918
-
The oncogenic potential of NANOG: An important cancer induction mediator.J Cell Physiol. 2021 Apr;236(4):2443-2458. doi: 10.1002/jcp.30063. Epub 2020 Sep 22. J Cell Physiol. 2021. PMID: 32960465 Review.
Cited by
-
Role of functional genomics in identifying cancer drug resistance and overcoming cancer relapse.Heliyon. 2023 Nov 14;10(1):e22095. doi: 10.1016/j.heliyon.2023.e22095. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38249111 Free PMC article. Review.
-
Development of a 3D-3 co-culture microbead consisting of cancer-associated fibroblasts and human umbilical vein endothelial cells for the anti-tumor drug assessment of lung cancer.Transl Lung Cancer Res. 2025 Jun 30;14(6):2159-2179. doi: 10.21037/tlcr-2025-525. Epub 2025 Jun 26. Transl Lung Cancer Res. 2025. PMID: 40673102 Free PMC article.
-
Resveratrol Analog 4-Bromo-Resveratrol Inhibits Gastric Cancer Stemness through the SIRT3-c-Jun N-Terminal Kinase Signaling Pathway.Curr Issues Mol Biol. 2021 Dec 22;44(1):63-72. doi: 10.3390/cimb44010005. Curr Issues Mol Biol. 2021. PMID: 35723384 Free PMC article.
-
P53/NANOG balance; the leading switch between poorly to well differentiated status in liver cancer cells.Front Oncol. 2024 May 23;14:1377761. doi: 10.3389/fonc.2024.1377761. eCollection 2024. Front Oncol. 2024. PMID: 38846985 Free PMC article. Review.
-
RhoC in association with TET2/WDR5 regulates cancer stem cells by epigenetically modifying the expression of pluripotency genes.Cell Mol Life Sci. 2022 Dec 5;80(1):1. doi: 10.1007/s00018-022-04645-z. Cell Mol Life Sci. 2022. PMID: 36469134 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials